Ibuprofen (Brufen) is a non-opioid, non-steroidal anti-inflammatory medicine that has antipyretic, analgesic, and anti-inflammatory properties.
It is used to treat the following conditions:
- Inflammatory and autoimmune rheumatic disorders
- Mild to moderate pain
- As an antipyretic (for fever)
- Osteoarthritis
- Dysmenorrhea
- Acute flares of gout
- Pericarditis
OTC (Over the counter) indications include:
- Fever
- Pain due to:
- Headache
- Migraine
- Sore throat
- Arthritis
- Sprains
- Menstrual pain
- Dental pain
- Minor muscles and joint pain
- Backache, and
- Cold and flu
Ibuprofen Dose in Adults
Ibuprofen for mild to moderate pain:
- Oral tablets: 200 mg to 800 mg twice or thrice daily (the usual daily dose is 1200 to 2400 mg per day
(Maximum daily dose is 3200 mg per day)
- According to the manufacturers labeling, the usual dose is 400 mg every 4 to 6 hours as needed to a maximum dose of 3200 mg per day.
- According to the American pain society:
- 200 to 400 mg every 4 to 6 hours to a maximum dose of 3200 mg per day.
Ibuprofen for fever:
- Intravenous ibuprofen initially 400 mg then 200 mg every 4 to 6 hours as needed
Ibuprofen for dysmenorrhea:
- 200 to 800 mg three to four times daily (usual dose is 1200 to 2400 mg/day for a maximum of 3 to 5 days.
- The manufacturers advise 400 mg every 4 hours as needed (maximum 3200 mg daily)
Ibuprofen for Acute flares of gout:
- 800 mg three times daily for 5 to 7 days.
- It should be started within 24 to 48 hours of symptoms onset and continued for 3 to 4 days after the resolution of symptoms.
Ibuprofen dose in patients with osteoarthritis:
- 400 to 800 mg three or four times daily (maximum: 3200 mg per day)
Ibuprofen dose in patients with Rheumatoid arthritis:
- 400 to 800 mg three or four times a day (maximum 3200 mg daily)
Ibuprofen dose in patients with Pericarditis:
Acute pericarditis:
- 600 mg every 8 hours for 7 to 14 days followed by a gradual tapering of the dose by 200 to 400 mg at every one to two weeks interval.
Recurrent Pericarditis:
- 600 mg every 8 hours (range 1200 to 2400 mg) for weeks to months until complete resolution of the symptoms followed by a gradual tapering of the dose by 200 mg per week.
Ibuprofen as OTC (over the counter labeling):
-
For analgesia and fever:
- 200 mg every 4 to 6 hours as needed (may increase the dose to 400 mg every 4 to 6 hours) to a maximum of 1200 mg per day.
- It should not be continued for more than 3 days for fever and for more than 10 days for pain
-
For migraine:
- 400 mg at the onset of symptoms (maximum 400 mg per 24 hours)
Ibuprofen Dose in Children
Ibuprofen dosage for pain relief:
- Infants and children less than 50 kgs (should not be used in children less than 6 months):
- 4 to 10 mg/kg/dose orally every 6 to 8 hours
Maximum single oral dose: 400 mg
Maximum daily oral dose: 40 mg/kg/day
-
Infants more than 6 months and less than 12 years of age:
- 10 mg/kg intravenously every 4 to 6 hours as needed (the maximum daily dose is 40 mg/kg/day or 2400 mg per day whichever is less.
-
Children and adolescents 12 to 17 years:
- 400 mg every 4 to 6 hours as needed to a maximum of 2400 mg per day.
Ibuprofen dose in fever:
- Infants >6 months of age, children, and adolescents:
- 5 to 10 mg/ kg/dose orally every 6 to 8 hours
A maximum single dose is 400 mg
Maximum daily dose: 40 mg/kg/day or 1200 mg/day unless directed by a physician (may use up to 2400 mg per day).
Intravenous Ibuprofen dose:
-
Infants more than 6 months and less than 12 years of age:
- 10 mg/kg intravenously
Maximum single intravenous dose: 400 mg every 4 to 6 hours as needed.
Maximum daily intravenous dose 40 mg/kg/day or 2400 mg/day whichever is less
-
Children and adolescents 12 to 17:
- 400 mg intravenously every 4 to 6 hours as needed
The maximum daily dose is 2400 mg per day
Ibuprofen dose in Juvenile idiopathic arthritis:
Oral dose in children:
- 30 to 40 mg/kg/day in 3 or 4 divided doses.
- Mild diseases may be treated with 20 mg/kg/day, severe diseases may be treated with 50 mg/kg/day.
The maximum single daily dose is 800 mg per day.
The maximum daily dose is 2400 mg//day.
Ibuprofen dose in Patent ductus arteriosus:
Intravenous ibuprofen dose:
- Infants weighing between 0.5 Kg to 1.5 kgs and less than 32 weeks of gestation:
- Initial dose of 10 mg/kg followed by two doses of 5 mg /kg at 24 and 48 hours of the initial dose
Ibuprofen OTC dosing for fever and pain:
Ibuprofen Dosing (Infants and Children 6 months to 11 years)
| Weight in Kgs | Weight in Pounds | Age | dosage in mg |
| 5.4 to 8.1 | 12 to 17 | 6 to 11 mo | 50 |
| 8.2 to 10.8 | 18 to 23 | 12 to 23 mo | 75 |
| 10.9 to 16.3 | 24 to 35 | 2 to 3 y | 100 |
| 16.4 to 21.7 | 36 to 47 | 4 to 5 y | 150 |
| 21.8 to 27.2 | 48 to 59 | 6 to 8 y | 200 |
| 27.3 to 32.6 | 60 to 71 | 9 to 10 y | 250 |
| 32.7 to 43.2 | 72 to 95 | 11 y | 300 |
Contraindications to Ibuprofen:
Alert!: US Boxed Warning
- It is contraindicated in cardiac bypass graft surgery.
- Non-steroidal anti-inflammatory drugs and so Ibuprofen has been associated with an increased risk of stroke and myocardial infarction.
- The risks increase when it is taken for a longer duration.
- NSAIDs increase the risk of serious gastrointestinal perforations, bleeding, and ulcerations.
- Patients, especially at risk of getting gastrointestinal related complications to include older patients, those with a previous history of peptic ulcer disease, and patients taking other medicines that may cause gastric ulceration.
- Hypersensitivity or allergy to ibuprofen, or any of its components.
- History of asthma, urticaria, or bronchial hyperreactivity to aspirin and other NSAIDs
- Patients who had CABG performed
- These conditions may affect neonates:
- Pulmonary atresia
- Coarctation of the aorta
- Tetralogy of Fallot
- Patients with severe thrombocytopenia and intracranial bleeding are at greater risk.
- Necrotizing enterocolitis
- Grave renal insufficiency
- Heart failure
- Hepatic impairments ranging from mild to severe
- Hyperkalemia
- The third trimester is the most important.
- During breastfeeding
Other warnings:
- Ibuprofen can increase bleeding time due to defective platelet adhesion or aggregation. It can also be associated with severe blood disorders.
- Hepatic impairment can occur. It is important to monitor LFTs
- Hyperkalemia can be caused by Ibuprofen and other NSAIDs. Hyperkalemia is more marked in patients taking potassium-sparing diuretics like spironolactone and drugs affecting the Renin-angiotensin-aldosterone system like ACE inhibitors and ARBs.
- It can cause nephrotoxicity. Patients who are dehydrated or taking other nephrotoxic medications can experience renal injury. Papillary necrosis may occur if ibuprofen is used long-term.
- It may also cause serious skin reactions like steven-johnson syndrome and exfoliative dermatitis.
- Aspirin-sensitive asthma patients are advised to avoid it
- It can cause aseptic meningitis.
|
5-Aminosalicylic Acid Derivatives |
Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. |
|
Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.) |
May enhance the antiplatelet effect of other Agents with Antiplatelet Properties. |
|
Alcohol (Ethyl) |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination. |
|
Aliskiren |
Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent. Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction. |
|
Aminoglycosides |
Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. |
|
Aminolevulinic Acid (Topical) |
Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). |
|
Angiotensin II Receptor Blockers |
May enhance the adverse/toxic effect of Nonsteroidal AntiInflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. |
|
Angiotensin-Converting Enzyme Inhibitors |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. |
|
Anticoagulants |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. Exceptions: Bemiparin; Enoxaparin; Heparin. |
|
Anticoagulants |
Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. Exceptions: Bemiparin; Enoxaparin; Heparin. |
|
Beta-Blockers |
|
|
Bisphosphonate Derivatives |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. |
|
Cephalothin |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. |
|
Collagenase (Systemic) |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. |
|
Corticosteroids (Systemic) |
May enhance the adverse/toxic effect of Nonsteroidal AntiInflammatory Agents (Nonselective). |
|
Dasatinib |
May enhance the anticoagulant effect of Agents with Antiplatelet Properties. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. |
|
Deferasirox |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. |
|
Deoxycholic Acid |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. |
|
Desmopressin |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin. |
|
Digoxin |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. |
|
Drospirenone |
Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone. |
|
Eplerenone |
Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. |
|
Fat Emulsion (Fish Oil Based) |
May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. |
|
Felbinac |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Glucosamine |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Haloperidol |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion. |
|
HydrALAZINE |
Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. |
|
Ibritumomab Tiuxetan |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. |
|
Ibrutinib |
May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. |
|
Inotersen |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Limaprost |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Lumacaftor |
May decrease the serum concentration of Ibuprofen. |
|
Multivitamins/Fluoride (with ADE) |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Multivitamins/Minerals (with ADEK, Folate, Iron) |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Multivitamins/Minerals (with AE, No Iron) |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Naftazone |
May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Obinutuzumab |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. |
|
Omega-3 Fatty Acids |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Pentosan Polysulfate Sodium |
May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents. |
|
Pentoxifylline |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Porfimer |
Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. |
|
Potassium-Sparing Diuretics |
Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. |
|
PRALAtrexate |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation. |
|
Probenecid |
May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. |
|
Prostacyclin Analogues |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Prostaglandins (Ophthalmic) |
Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). |
|
Quinolones |
Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. |
|
Salicylates |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. |
|
Serotonin/Norepinephrine Reuptake Inhibitors |
May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). |
|
Tacrolimus (Systemic) |
Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). |
|
Thiazide and Thiazide-Like Diuretics |
May enhance the nephrotoxic effect of Nonsteroidal AntiInflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. |
|
Thrombolytic Agents |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. |
|
Tipranavir |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Tolperisone |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Tricyclic Antidepressants (Tertiary Amine) |
May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). |
|
Vancomycin |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. |
|
Verteporfin |
Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. |
|
Vitamin E (Systemic) |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Voriconazole |
May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased. |
|
Risk Factor D (Consider therapy modification) |
|
|
Apixaban |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. |
|
Bemiparin |
Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. |
|
Bemiparin |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. |
|
Bile Acid Sequestrants |
May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. |
|
CycloSPORINE (Systemic) |
Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs). Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs. |
|
Dabigatran Etexilate |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. |
|
Diclofenac (Systemic) |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAIDs). Avoid the use of diclofenac/misoprostol with other NSAIDs. |
|
Edoxaban |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. |
|
Enoxaparin |
Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding. |
|
Enoxaparin |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding. |
|
Heparin |
Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required. |
|
Heparin |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required. |
|
Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry) |
May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur. Management: Avoid combination when possible. If used, monitor more closely for evidence of bleeding. Discontinue herbal products with anticoagulant or antiplatelet actions 2 weeks prior to surgical, dental, or invasive procedures. |
|
Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry) |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed. |
|
Imatinib |
Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response. Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib. Available evidence suggests other NSAIDs do not interact in a similar manner. |
|
Lithium |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. |
|
Loop Diuretics |
Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended. |
|
Methotrexate |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate. Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate. |
|
PEMEtrexed |
Ibuprofen may increase the serum concentration of PEMEtrexed. Management: In patients with an estimated creatinine clearance of 45 to 79 mL/min, avoid ibuprofen for 2 days before, the day of, and 2 days following the administration of pemetrexed. Monitor for increased pemetrexed toxicities if combined. |
|
Rivaroxaban |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. |
|
Salicylates |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Exceptions: Choline Magnesium Trisalicylate. |
|
Selective Serotonin Reuptake Inhibitors |
May enhance the antiplatelet effect of Nonsteroidal AntiInflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk. |
|
Sincalide |
Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. |
|
Sodium Phosphates |
May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely. |
|
Tenofovir Products |
Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose. |
|
Vitamin K Antagonists (eg, warfarin) |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. |
|
Risk Factor X (Avoid combination) |
|
|
Acemetacin |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Aminolevulinic Acid (Systemic) |
Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). |
|
Dexibuprofen |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen. |
|
Dexketoprofen |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Floctafenine |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Ketorolac (Nasal) |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Ketorolac (Systemic) |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Macimorelin |
Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. |
|
Mifamurtide |
Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. |
|
Morniflumate |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). |
|
Omacetaxine |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL. |
|
Pelubiprofen |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Phenylbutazone |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Talniflumate |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Tenoxicam |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Urokinase |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. |
|
Zaltoprofen |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
Avoid in advanced renal disease.
According to the KDIGO 2012 guidelines:
- Avoid use if eGFR is less than 30 ml/min
- eGFR of 30 -60 ml/min: avoid use if there is a risk of worsening renal failure
Dose in liver disease:
No dose adjustment has been provided by the manufacturer in liver diseases. However, it should be used with caution in advanced liver disease.
How to administer Ibuprofen?
Oral ibuprofen should best be taken with water or milk after meals. The intravenous formulation should be infused over at least 30 minutes.
Pregnancy Risk Factor C ( <30 weeks), D (> 30 weeks)
- Some studies have shown that birth defects can be found.
- Data on teratogenicity are not consistent.
- Following pregnancy, ibuprofen exposure has been shown to have the following non-teratogenic effects:
- Pre-birth constriction of the arteriosus ductus
- The newborn may have persistent pulmonary hypertension.
- Oligohydramnios,
- Necrotizing enterocolitis,
- Failure or dysfunction of the renal system
- Intracranial hemorrhage
- Ibuprofen is sometimes preferred to other NSAIDs during pregnancy for migraine treatment.
- However, there are other types of medicine that may be more effective than NSAIDs. Infertility has also been linked to NSAIDs, but this can be reversed by stopping taking the medication.
Ibuprofen during breastfeeding:
- Ibuprofen is small enough to enter breastmilk in small amounts.
- No adverse effects have been reported in infants.
- Ibuprofen might be preferable to other NSAIDs in postpartum pain.
- When taken in the recommended dosages, Ibuprofen is considered compatible with breastfeeding by the WHO.
Common Side effects of ibuprofen:
- Common side effects include an elevation in liver enzymes and anemia.
Less common side effects include:
-
- dizziness, headache, and vertigo
- edema, rash, and pruritis
- Fluid retention
- Gastric ulceration, heartburn, dyspepsia, gastrointestinal bleeding, nausea and vomiting, abdominal pain, cramps, constipation and bloating
- prolonged bleeding time
- Tinnitus and renal injury
-
Other less common side effects include:
- Hypotension, syncope, and tachycardia
- anxiety, malaise, and diaphoresis
- ecchymosis, rectal bleeding, and stomatitis
- dysuria, oliguria, and proteinuria
- leukopenia, infections, and sepsis
- asthenia, tremors, and interstitial nephritis
Monitor:
- Patients should monitor Blood CBC, Chemistry, Renal functions, and liver functions.
- Patients should be monitored for weight gain, bleeding, bruising, and, gastrointestinal side effects.
Mechanism of action of Ibuprofen:
- It reverses the inhibition of cyclooxygenase 1, 2 (COX 1), which results in decreased prostaglandin formation. It is antipyretic, analgesic and anti-inflammatory.
Onset of action: 30 to 60 minutes (The maximum effect: 2 - 4 hours) The total duration of action is 6 - 8 hours. It is rapidly absorbed with a bioavailability of 80% and is 99% protein bound. Metabolism is via the liver Excretion is via urine (metabolites) Half-life elimination is about 0.5 to 1.5 hours.
Ibuprofen Brand Names (International):
- Actiprofen
- Actron
- Adagin
- Adex 200
- Adex Liqui-Gels
- Advel
- Advil
- Afebril
- Aktren
- Algofen
- Am-Fam 400
- Anafen
- Anco
- Antarene
- Arfen
- Argifen
- Asfen-400
- Balkaprofen
- Bebyzal
- Bestafen
- Bifen
- Bofen
- Brufen
- Brufen 400
- Brufen Forte
- Brufen Retard
- Brufen Syrup for Children
- Brufort
- Brupro
- Bufect
- Bufect Forte
- Buplex
- Buprex
- Buprophar
- Burana
- Butafen
- Carol
- Cefen
- Cuprofen
- Dafen-Q
- Dalsy
- Degiton
- Diffutab SR 600
- Dolafen
- Dolan FP
- Dolex
- Dolgit
- Dolocyl
- Dolomax
- Doloral
- Dolormin
- Dolprin
- Druisel
- Easofen
- Evofen
- Expanfen
- Extrapan Gel
- Farsifen Forte
- Febratic
- Febryn
- Fenatic
- Fenbid
- Fenpaed
- Fever-Free
- Flamex
- Focus
- Genofen
- Gofen
- Gyno-neuralgin
- Hagifen
- Ibufac
- Ibufen
- Ibuflam
- Ibufug
- Ibugesic
- Ibugic
- Ibulgan
- Ibumetin
- Ibunorm
- Ibupirac
- Ibuprofen
- Ibusal
- Ibuspan
- Ibutop
- Imet
- Infacalm
- Inufen
- Ipren
- Iprox
- Ipufen
- Irfen
- Junifen
- Liptan
- Medicol
- Medicol Advance
- Mensoton
- Mepabrufen
- Mofen
- Moris
- Moris Forte
- Motrin
- Mutrim
- Neoprofen
- Neutropain
- Nobafon
- Noritis
- Novogent
- Nureflex
- Nurofen
- Nurofen for Children
- Nurofen Gel
- Nurofen Pro san sucre
- Nuroffen
- Nurosan
- Optifen
- Opturem
- Ostarin
- P-Fen
- Panafen
- Pedea
- Peflam
- Perfen
- Perofen
- Profen
- Profinal
- Proris
- Prosinal
- Provon
- Quadrax
- Rafen
- Ranofen
- RatioDolor
- Remofen
- Rhelafen
- Rhelafen Forte
- Rheumanox
- Rupan
- Ruprofen
- Sapofen
- Spedifen
- Speedifen
- Spifen
- Syntofene
- Tabalon
- Tabalon 400
- Tarein
- Taskine
- Tefin
- Tenvalin
- Thomaprodol
- Ufen
- Upfen
- Uprofen
- Urem
- Vantril
- Xfen Flashtab
- Zofen
- Zorafen
Ibuprofen Brand Names in Pakistan
Ibuprofen Syrup 100 mg/5ml |
|
| Al-Fen | Alina Combine Pharmaceuticals (Pvt) Ltd. |
| Hebofen | Heal Pharmaceuticals Pvt Ltd |
| Micafen | Max Pharmaceuticals |
Ibuprofen Susp 100 mg/5ml |
|
| Actifen | Glaxosmithkline |
| Aksofen | Akson Pharmaceuticals (Pvt) Ltd. |
| Ambrofen | Jawa Pharmaceuticals(Pvt) Ltd. |
| Ambrofen | Jawa Pharmaceuticals(Pvt) Ltd. |
| Amofen | Ameer Pharma |
| Artijesic | Medisearch Pharmacal(Pvt) Ltd |
| Artijesic | Medisearch Pharmacal(Pvt) Ltd |
| Azofin | Alkemy Pharmaceutical Laboratories (Private) Ltd. |
| Azofin | Alkemy Pharmaceutical Laboratories (Private) Ltd. |
| Befen | Rakaposhi Pharmaceutical (Pvt) Ltd. |
| Bepofen | Lotus Pharmaceuticals (Pvt) Ltd |
| Bepofen | Lotus Pharmaceuticals (Pvt) Ltd |
| Bepofen | Lotus Pharmaceuticals (Pvt) Ltd |
| Biofen | Bio Labs (Pvt) Ltd. |
| Bludol | Standpharm Pakistan (Pvt) Ltd. |
| Blufen | Bloom Pharmaceuticals (Pvt) Ltd. |
| Brosun | Hisun Pharmaceuticals |
| Brufed | Fedro Pharmaceutical |
| Brufedin | Ardin Pharmaceuticals |
| Brufedin | Ardin Pharmaceuticals |
| Brufen | Abbott Laboratories (Pakistan) Limited. |
| Brufen | Abbott Laboratories (Pakistan) Limited. |
| Brugesic | Umersons |
| Deltafen | Delta Pharma (Pvt) Ltd. |
| Dolocol | Semos Pharmaceuticals (Pvt) Ltd. |
| Dorafen | Dosaco Laboratories |
| Eprofen | Epoch Pharmaceutical |
| Eprofen | Epoch Pharmaceutical |
| Everfen | Evergreen Pharmaceuticals Pvt Limited |
| Exifin | Genix Pharma (Pvt) Ltd |
| Fenbro | Stanley Pharmaceuticals (Pvt) Ltd. |
| Fenober | Trigon Pharmaceuticals Pakistan (Pvt) Ltd. |
| Fenober | Trigon Pharmaceuticals Pakistan (Pvt) Ltd. |
| Fenober | Trigon Pharmaceuticals Pakistan (Pvt) Ltd. |
| Flumax | Max Pharmaceuticals |
| Fynkoben | Fynk Pharmaceuticals |
| Glare Sus | Shrooq Pharmaceuticals |
| Hibtol | Don Valley Pharmaceuticals (Pvt) Ltd. |
| Hugon | Hizat Pharmaceutical Industries (Pvt) Ltd. |
| Ibofen | Nova Med Pharmaceuticals |
| Ibofen | Nova Med Pharmaceuticals |
| Ibofen | Nova Med Pharmaceuticals |
| Iboz | Z-Jans Pharmaceutical (Pvt) Ltd. |
| Ibu-Gesic | Polyfine Chempharma (Pvt) Ltd. |
| Ibu-U | Universal Pharmaceuticals (Pvt) Ltd |
| Ibucil | Mediceena Pharma (Pvt) Ltd. |
| Ibugen | Genera Pharmaceuticals |
| Ibugesic | Wilsons Pharmaceuticals |
| Ibulexin | Lexicon Pharmaceuticals (Pvt) Ltd. |
| Ibuped | Alliance Pharmaceuticals (Pvt) Ltd. |
| Ibuprofen | Lisko Pakistan (Pvt) Ltd |
| Ibuprofen | British Pharmaceuticals Ltd |
| Ibuprofen | Lisko Pakistan (Pvt) Ltd |
| Ibuprofen | Lisko Pakistan (Pvt) Ltd |
| Ibuprofen | Munawar Pharma (Pvt) Ltd. |
| Ibuprofen | Munawar Pharma (Pvt) Ltd. |
| Ibupros | Paramount Pharmaceuticals |
| Ibupros | Paramount Pharmaceuticals |
| Ibupros | Paramount Pharmaceuticals |
| Iburfen | Mediate Pharmaceuticals (Pvt) Ltd |
| Iburin | Hamaz Pharmaceutical (Pvt) Ltd. |
| Ibuser | Star Laboratories (Pvt) Ltd. |
| Ibuser | Star Laboratories (Pvt) Ltd. |
| Ibusim | Simz Pharmaceuticals |
| Imcofen | Imco Pharmaceuticals Laboratories |
| Inflam | Spencer Pharma |
| Inflam | Spencer Pharma |
| Inzel | Raazee Theraputics (Pvt) Ltd. |
| Iodofen | Ideal Pharmaceutical Industries |
| Isen | Ici Pakistan Ltd. |
| Jaefen | Irza Pharma (Pvt) Ltd. |
| Jaefen | Irza Pharma (Pvt) Ltd. |
| Lemach | Leama Chemi Pharma (Pvt.) Ltd. |
| Mb-Fen | Multinational Buisness Link |
| Medfen | Medicraft Pharmaceuticals (Pvt) Ltd. |
| Medibrufen | Mediate Pharmaceuticals (Pvt) Ltd |
| Medibrufen | Mediate Pharmaceuticals (Pvt) Ltd |
| Megafen | Albro Pharma |
| Mufen | Macquins International |
| Nenfen | Nenza Pharmaceuticals (Pvt) Limited |
| Neoprofen | Neo Medix |
| Neuprofen | Neutro Pharma (Pvt) Ltd. |
| Novofen | Krka-Pak Pharmaceutical & Chemical Works |
| Ocefen | Safe Pharmaceutical (Pvt) Ltd. |
| Ofen | Libra Pharmaceuticals (Pvt) Ltd |
| Onyfen | Onyx Pharmaceutical |
| Ottofen | Eros Pharmaceuticals |
| Paincare | Care & Cure |
| Panil | Delux Chemical Industries |
| Pedifen | Ferozsons Laboratoies Ltd. |
| Pedifen | Ferozsons Laboratoies Ltd. |
| Phine | Mac & Rans Pharmaceuticals (Pvt) Ltd |
| Pironec | Atlantic Pharmaceuticals (Pvt) Ltd. |
| Pironec Plus | Atlantic Pharmaceuticals (Pvt) Ltd. |
| Prexol | Asian Agencies |
| Proflam | Polyfine Chempharma (Pvt) Ltd. |
| Prosta | Global Pharmaceuticals |
| Pyrofen | Sharex Laboratories (Pvt.) Ltd. |
| Pyrofen | Sharex Laboratories (Pvt.) Ltd. |
| Q-Fen | Hassan Pharmaceuticals (Pvt) Ltd. |
| Remofen | Syntex Pharmaceuticals |
| Rhunor | Wahabsons Pharma |
| Ruberin | W.Woodward Pakistan (Pvt) Ltd. |
| Rumafen | Atco Laboratories Limited |
| Rumatofen | Karachi Pharmaceutical Laboratory |
| Rumin | Ankaz Pharmex (Pvt) Ltd. |
| Semorfen | Semos Pharmaceuticals (Pvt) Ltd. |
| Stabru | Standard Drug Co. |
| Synofen | Synchro Pharmaceuticals |
| Tabalon | Sanofi Aventis (Pakistan) Ltd. |
| Werridal | Werrick Pharmaceuticals |
| Wilfen | Wilshire Laboratories (Pvt) Ltd. |
| Xiben | Pacific Pharmaceuticals Ltd. |
| Zayfen | Zaynoon Pharmaceuticals |
| Zefen | Xenon Pharmaceuticals (Pvt) Ltd. |
| Zefrin | Fozan Pharmaceuticals Industriers (Pvt) Ltd |
| Zintafen | Zinta Pharmaceuticals Industries |
| Zufen | Zanctok Pharmaceuticals |
Ibuprofen Suspension 200 mg/5ml |
|
| Brufen | Abbott Laboratories (Pakistan) Limited. |
Ibuprofen Oral Solution 100 Mg |
|
| Ibunol | Miracle Pharmaceuticals(Pvt) Ltd |
Ibuprofen Cream 10 % W/W |
|
| Ambrofen | Jawa Pharmaceuticals(Pvt) Ltd. |
| Artijesic | Medisearch Pharmacal(Pvt) Ltd |
| Brufen | Abbott Laboratories (Pakistan) Limited. |
| Ibugray | Gray`S Pharmaceuticals |
| Karbufen | Genix Pharma (Pvt) Ltd |
Ibuprofen Patches: 30 mg |
|
| Kefentech | Matrix Pharma |
Ibuprofen Gel 10 % W/W |
|
| Rumafen | Atco Laboratories Limited |
Ibuprofen 200 mg Tablets |
|
| Actifen | Glaxosmithkline |
| Al-Fen | Alina Combine Pharmaceuticals (Pvt) Ltd. |
| Ambrofen | Jawa Pharmaceuticals(Pvt) Ltd. |
| Ambrofen | Jawa Pharmaceuticals(Pvt) Ltd. |
| Amrofen | Amros Pharmaceuticals. |
| Anglofen | Euro Pharma International |
| Arufen | Progressive Laboratories |
| B-Fen | Helicon Pharmaceutek Pakistan (Pvt) Ltd. |
| Baprofen | Batala Pharmaceuticals. |
| Baprofen | Batala Pharmaceuticals. |
| Bludol | Standpharm Pakistan (Pvt) Ltd. |
| Boschofen | Bosch Pharmaceuticals (Pvt) Ltd. |
| Bravofen | Mega Pharmaceuticals (Pvt) Ltd |
| Brufen | Abbott Laboratories (Pakistan) Limited. |
| Brufen | Abbott Laboratories (Pakistan) Limited. |
| Bumex | Multinational Buisness Link |
| Dolocol | Semos Pharmaceuticals (Pvt) Ltd. |
| Dorafen | Dosaco Laboratories |
| Eurofen | Euro Pharma International |
| Everfen | Evergreen Pharmaceuticals Pvt Limited |
| Fenober | Trigon Pharmaceuticals Pakistan (Pvt) Ltd. |
| Ferrofen | Ferro Pharmaceutical Laboratories |
| Ferrofen | Ferro Pharmaceutical Laboratories |
| Fufen | Flow Pharmaceuticals (Pvt) Ltd. |
| Fufen | Flow Pharmaceuticals (Pvt) Ltd. |
| Hibtol | Don Valley Pharmaceuticals (Pvt) Ltd. |
| Hifen | Helix Pharma (Private) Limited |
| Hizofen | Hizat Pharmaceutical Industries (Pvt) Ltd. |
| Ibowin | Jinnah Pharmaceuticals |
| Ibu | Unexo Labs (Pvt) Ltd. |
| Ibu | Unexo Labs (Pvt) Ltd. |
| Ibufin | Medicaids Pakistan (Pvt) Ltd. |
| Ibufin | Medicaids Pakistan (Pvt) Ltd. |
| Ibulexin | Lexicon Pharmaceuticals (Pvt) Ltd. |
| Ibumid | P.D.H. Pharmaceuticals (Pvt) Ltd. |
| Ibumid | P.D.H. Pharmaceuticals (Pvt) Ltd. |
| Ibuprofen | Siza International (Pvt) Ltd. |
| Ibuprofen | Munawar Pharma (Pvt) Ltd. |
| Ibuprofen | Siza International (Pvt) Ltd. |
| Ibuprofen | Zafa Pharmaceutical Laboratories (Pvt) Ltd. |
| Ibuprofen | Unipharma (Pvt) Ltd. |
| Ibuprofen | Unipharma (Pvt) Ltd. |
| Ibuprofen | Zafa Pharmaceutical Laboratories (Pvt) Ltd. |
| Ibuprofen | Geofman Pharmaceuticals |
| Ibuprofen | Unison Chemical Works |
| Ibuprofen | Geofman Pharmaceuticals |
| Iburin | Hamaz Pharmaceutical (Pvt) Ltd. |
| Iburin | Hamaz Pharmaceutical (Pvt) Ltd. |
| Ibuser | Star Laboratories (Pvt) Ltd. |
| Ifen | Adamjee Pharmaceuticals (Pvt) Ltd. |
| Igrafen | Specific Research Laboratories |
| Inflam | Spencer Pharma |
| Iodofen | Ideal Pharmaceutical Industries |
| Iodofen | Ideal Pharmaceutical Industries |
| Jaefen | Irza Pharma (Pvt) Ltd. |
| Jaefen | Irza Pharma (Pvt) Ltd. |
| Kayfen | Karachi Chemical Industries |
| Medibrrufen | Mediate Pharmaceuticals (Pvt) Ltd |
| Medibru | Medera Pharmaceuticals (Pvt) Ltd. |
| Megafen | Albro Pharma |
| Megafen | Albro Pharma |
| Mufen | Macquins International |
| Nenfen | Nenza Pharmaceuticals (Pvt) Limited |
| Neo-Butinal | Schazoo Zaka |
| Neo-Butinal | Schazoo Zaka |
| Novofen | Krka-Pak Pharmaceutical & Chemical Works |
| Novofen | Krka-Pak Pharmaceutical & Chemical Works |
| Novofen | Krka-Pak Pharmaceutical & Chemical Works |
| Ocefen | Safe Pharmaceutical (Pvt) Ltd. |
| Ocefen | Safe Pharmaceutical (Pvt) Ltd. |
| Ofcin | Obsons Pharmaceuticals |
| Ottofen | Eros Pharmaceuticals |
| Pango | Efroze Chemical Industries (Pvt) Ltd. |
| Pango | Efroze Chemical Industries (Pvt) Ltd. |
| Pharfen | Pharmacare Laboratories (Pvt) Ltd. |
| Pharfen | Pharmacare Laboratories (Pvt) Ltd. |
| Pharfen | Pharmacare Laboratories (Pvt) Ltd. |
| Profen | Ferozsons Laboratoies Ltd. |
| Profen | Ferozsons Laboratoies Ltd. |
| Promin | Pharmawise Labs. (Pvt) Ltd. |
| Promin | Pharmawise Labs. (Pvt) Ltd. |
| Prufo | Valor Pharmaceuticals |
| Pyrofen | Sharex Laboratories (Pvt.) Ltd. |
| Regofen | Regent Laboratories Ltd. |
| Resfen | Rasco Pharma |
| Resfen | Rasco Pharma |
| Rumat | Ferroza International Pharmaceuticals (Pvt) Ltd. |
| Rumatofen | Karachi Pharmaceutical Laboratory |
| Rumatofen | Karachi Pharmaceutical Laboratory |
| Rumin | Ankaz Pharmex (Pvt) Ltd. |
| Semorfen | Semos Pharmaceuticals (Pvt) Ltd. |
| Suprofen | Kohs Pharmaceuticals |
| Tagafin | Tagma Pharma (Pvt) Ltd. |
| True-Fen | Mass Pharma (Private) Limited |
| True-Fen | Mass Pharma (Private) Limited |
| Uniprofen | Unison Chemical Works |
| Vee Bufen | Venus Pharma |
| Wilfen | Wilshire Laboratories (Pvt) Ltd. |
| Wilfen | Wilshire Laboratories (Pvt) Ltd. |
| Zufen | Zanctok Pharmaceuticals |
Ibuprofen 400 mg Tablets |
|
| Actifen | Glaxosmithkline |
| Aksofen | Akson Pharmaceuticals (Pvt) Ltd. |
| Al-Fen | Alina Combine Pharmaceuticals (Pvt) Ltd. |
| Ambrofen | Jawa Pharmaceuticals(Pvt) Ltd. |
| Ambrofen | Jawa Pharmaceuticals(Pvt) Ltd. |
| Amrofen | Amros Pharmaceuticals. |
| Anglofen | Euro Pharma International |
| Apro Tablet | Ambrosia Pharmaceuticals |
| Azofin | Alkemy Pharmaceutical Laboratories (Private) Ltd. |
| B-Fen | Helicon Pharmaceutek Pakistan (Pvt) Ltd. |
| Baprofen | Batala Pharmaceuticals. |
| Baprofen | Batala Pharmaceuticals. |
| Bludol | Standpharm Pakistan (Pvt) Ltd. |
| Boschofen | Bosch Pharmaceuticals (Pvt) Ltd. |
| Bravofen | Mega Pharmaceuticals (Pvt) Ltd |
| Brufedin | Ardin Pharmaceuticals |
| Brufen | Abbott Laboratories (Pakistan) Limited. |
| Brufen | Abbott Laboratories (Pakistan) Limited. |
| Cayprof | Caylex Pharmaceuticals (Pvt) Ltd. |
| Deltafen | Delta Pharma (Pvt) Ltd. |
| Dolocol Forte | Semos Pharmaceuticals (Pvt) Ltd. |
| Dolofen | Agp (Private) Ltd. |
| Dorafen | Dosaco Laboratories |
| Eprofen | Epoch Pharmaceutical |
| Eprofen | Epoch Pharmaceutical |
| Eurofen | Euro Pharma International |
| Everfen | Evergreen Pharmaceuticals Pvt Limited |
| Fenflex | Pakheim Internanational Pharma |
| Ferrofen | Ferro Pharmaceutical Laboratories |
| Ferrofen | Ferro Pharmaceutical Laboratories |
| Fufen | Flow Pharmaceuticals (Pvt) Ltd. |
| Fufen | Flow Pharmaceuticals (Pvt) Ltd. |
| Hebofen | Heal Pharmaceuticals Pvt Ltd |
| Hifen | Helix Pharma (Private) Limited |
| Hizofen | Hizat Pharmaceutical Industries (Pvt) Ltd. |
| Ibowin | Jinnah Pharmaceuticals |
| Ibu | Unexo Labs (Pvt) Ltd. |
| Ibu | Unexo Labs (Pvt) Ltd. |
| Ibucare | Adcare Pharma |
| Ibucare | Aims Traders |
| Ibufin | Medicaids Pakistan (Pvt) Ltd. |
| Ibufin | Medicaids Pakistan (Pvt) Ltd. |
| Ibugen | Genera Pharmaceuticals |
| Ibugen | Genera Pharmaceuticals |
| Ibugen | Genera Pharmaceuticals |
| Ibugray | Gray`S Pharmaceuticals |
| Ibumid | P.D.H. Pharmaceuticals (Pvt) Ltd. |
| Ibumid | P.D.H. Pharmaceuticals (Pvt) Ltd. |
| Ibuprofen | Zafa Pharmaceutical Laboratories (Pvt) Ltd. |
| Ibuprofen | Munawar Pharma (Pvt) Ltd. |
| Ibuprofen | Zafa Pharmaceutical Laboratories (Pvt) Ltd. |
| Ibuprofen | Siza International (Pvt) Ltd. |
| Ibuprofen | Geofman Pharmaceuticals |
| Ibupulse | Pulse Pharmaceuticals |
| Iburin | Hamaz Pharmaceutical (Pvt) Ltd. |
| Iburin | Hamaz Pharmaceutical (Pvt) Ltd. |
| Ibuser | Star Laboratories (Pvt) Ltd. |
| Ifen | Adamjee Pharmaceuticals (Pvt) Ltd. |
| Inflam | Spencer Pharma |
| Iodofen | Ideal Pharmaceutical Industries |
| Jaefen | Irza Pharma (Pvt) Ltd. |
| Jaefen | Irza Pharma (Pvt) Ltd. |
| Kanflam | Medisure Laboratories Pakistan (Pvt.) Ltd. |
| Kayfen | Karachi Chemical Industries |
| Mb-Fen | Multinational Buisness Link |
| Medibru | Medera Pharmaceuticals (Pvt) Ltd. |
| Medibrufen | Mediate Pharmaceuticals (Pvt) Ltd |
| Megafen | Albro Pharma |
| Mufen | Macquins International |
| Nenfen | Nenza Pharmaceuticals (Pvt) Limited |
| Neo-Butinal | Schazoo Zaka |
| Neo-Butinal | Schazoo Zaka |
| Novofen | Krka-Pak Pharmaceutical & Chemical Works |
| Novofen | Krka-Pak Pharmaceutical & Chemical Works |
| Novofen | Krka-Pak Pharmaceutical & Chemical Works |
| Ocefen | Safe Pharmaceutical (Pvt) Ltd. |
| Ocefen | Safe Pharmaceutical (Pvt) Ltd. |
| Ofen | Libra Pharmaceuticals (Pvt) Ltd |
| Ottofen | Eros Pharmaceuticals |
| Pabrofen | Drug Pharm (Pvt) Ltd. |
| Pango | Efroze Chemical Industries (Pvt) Ltd. |
| Pango | Efroze Chemical Industries (Pvt) Ltd. |
| Panil | Delux Chemical Industries |
| Pesudomol Fort | Ambrosia Pharmaceuticals |
| Pharfen | Pharmacare Laboratories (Pvt) Ltd. |
| Pharfen | Pharmacare Laboratories (Pvt) Ltd. |
| Pharfen | Pharmacare Laboratories (Pvt) Ltd. |
| Profen | Ferozsons Laboratoies Ltd. |
| Profen | Ferozsons Laboratoies Ltd. |
| Promin | Pharmawise Labs. (Pvt) Ltd. |
| Promin | Pharmawise Labs. (Pvt) Ltd. |
| Propen | Global Pharmaceuticals |
| Prufo | Valor Pharmaceuticals |
| Pyrofen | Sharex Laboratories (Pvt.) Ltd. |
| Rapifen | Pharmix Laboratories (Private) Limited. |
| Regofen | Regent Laboratories Ltd. |
| Remofen | Syntex Pharmaceuticals |
| Remofen | Syntex Pharmaceuticals |
| Resfen | Rasco Pharma |
| Resfen | Rasco Pharma |
| Rexaprofen | S.J. & G. Fazul Ellahie (Pvt) Ltd. |
| Rumat | Ferroza International Pharmaceuticals (Pvt) Ltd. |
| Rumatofen | Karachi Pharmaceutical Laboratory |
| Rumatofen | Karachi Pharmaceutical Laboratory |
| Rumin | Ankaz Pharmex (Pvt) Ltd. |
| Semorfen | Semos Pharmaceuticals (Pvt) Ltd. |
| Semorfen | Semos Pharmaceuticals (Pvt) Ltd. |
| Suprofen | Kohs Pharmaceuticals |
| Tagafin | Tagma Pharma (Pvt) Ltd. |
| Tesco | Nimrall Laboratories |
| Tesco | Nimrall Laboratories |
| True-Fen | Mass Pharma (Private) Limited |
| True-Fen | Mass Pharma (Private) Limited |
| Unifen | Tg Pharma |
| Uniprofin | Unison Chemical Works |
| Varinac | Genome Pharmaceuticals (Pvt) Ltd |
| Vee Bufen | Venus Pharma |
| Vee Bufen | Venus Pharma |
| Wefen | Webros Pharmaceuticals |
| Wilfen | Wilshire Laboratories (Pvt) Ltd. |
| Wilfen | Wilshire Laboratories (Pvt) Ltd. |
| Xiben | Pacific Pharmaceuticals Ltd. |
| Zefen | Xenon Pharmaceuticals (Pvt) Ltd. |
| Zefen | Xenon Pharmaceuticals (Pvt) Ltd. |
| Zintafen | Zinta Pharmaceuticals Industries |
| Zufen | Zanctok Pharmaceuticals |
Ibuprofen 600 mg Tablets |
|
| Actifen | Glaxosmithkline |
| Brufen | Abbott Laboratories (Pakistan) Limited. |
| Ibu | Unexo Labs (Pvt) Ltd. |
| Ibu | Unexo Labs (Pvt) Ltd. |
| Ibu-Slow | Europak Pharma (Pvt) Ltd |
| Ibucil | Mediceena Pharma (Pvt) Ltd. |
| Ifen | Adamjee Pharmaceuticals (Pvt) Ltd. |
| Inflam | Spencer Pharma |
| Panil | Delux Chemical Industries |
| Profen | Ferozsons Laboratoies Ltd. |
| Profen | Ferozsons Laboratoies Ltd. |
| Prosta | Global Pharmaceuticals |
| Prufo | Valor Pharmaceuticals |
Ibuprofen SR 800 mg Tablets |
|
| Brufen Retard | Abbott Laboratories (Pakistan) Limited. |
Ibuprofen 200 mg Capsules |
|
| Ibuquik | Zafa Pharmaceutical Laboratories (Pvt) Ltd. |
| Ibusoft | Zafa Pharmaceutical Laboratories (Pvt) Ltd. |
Ibuprofen 400 mg Capsules |
|
| Ibuquik | Zafa Pharmaceutical Laboratories (Pvt) Ltd. |
Ibuprofen 100 mg Powder |
|
| Brucam | Hoover Pharmaceuticals (Pvt) Ltd |
 Injection for familial chylomicronemia syndrome.jpeg)
